Ipamorelin Guide

Ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH2) is a synthetic pentapeptide — five amino acids — engineered to be a highly selective agonist of the growth hormone secretagogue receptor 1a (GHSR-1a), the same receptor targeted by ghrelin. It was originally developed by Novo Nordisk in the 1990s and remains the reference compound for GHRP selectivity research.

The critical distinction that sets ipamorelin apart from all other GHRPs is its extraordinary receptor selectivity. While GHRP-6 and GHRP-2 also activate GHSR-1a, they also bind adjacent receptors that drive cortisol and prolactin release, and trigger significant ghrelin-like appetite stimulation. Ipamorelin does none of this at standard doses — it releases GH and essentially nothing else. This is not a marketing claim but a verified pharmacological property established in multiple studies.

Mechanistically, ipamorelin acts as a GHSR-1a agonist and synergizes with endogenous GHRH (Growth Hormone Releasing Hormone) produced by the hypothalamus. When administered alongside a GHRH analogue such as CJC-1295, the two mechanisms combine to produce a supraphysiologic but still pulsatile GH response — 3 to 4 times the GH release of either compound used alone.

Pentapeptide structure engineered for maximum GHSR-1a selectivity with minimal off-target receptor binding.

Short injection-based half-life produces a physiologic pulsatile GH burst rather than a sustained flat elevation.

No elevation of cortisol, prolactin, or ACTH at standard doses — the defining pharmacological property of ipamorelin.

Ipamorelin binds the growth hormone secretagogue receptor 1a on pituitary somatotrophs — the same receptor that ghrelin activates. This binding triggers a calcium-dependent signaling cascade that stimulates GH synthesis and pulsatile release from the pituitary gland. The key difference from ghrelin is that ipamorelin does not activate the parallel receptor pathways that drive hunger, cortisol, and prolactin release.

Ipamorelin's GH release is dramatically amplified when endogenous GHRH signaling is present or when an exogenous GHRH analogue (like CJC-1295) is co-administered. The GHSR-1a and GHRH receptor pathways are genuinely synergistic at the pituitary — both are needed simultaneously to produce a maximal GH pulse. This is the mechanistic basis for the CJC-1295 + ipamorelin stack being so much more effective than either alone.

Elevated GH from repeated ipamorelin pulses signals the liver to produce Insulin-like Growth Factor 1 (IGF-1), which mediates most of GH's anabolic and body composition effects. Regular ipamorelin use (2–3x daily) raises IGF-1 approximately 15–30% from baseline. When stacked with CJC-1295 DAC, the IGF-1 rise can exceed 50% — important context for monitoring and staying within physiologic reference ranges.

Unlike some peptides and GH secretagogues, ipamorelin shows no evidence of receptor desensitization at standard doses with ongoing use. This is mechanistically explained by its pulsatile delivery pattern — the receptor is not chronically occupied. Continuous GHSR-1a stimulation (as with some small molecule secretagogues) produces tachyphylaxis; pulsatile agonism as produced by ipamorelin injections does not.

GHSR-1a Agonism: Ipamorelin binds the growth hormone secretagogue receptor 1a on pituitary somatotrophs — the same receptor that ghrelin activates. This binding triggers a calcium-dependent signaling cascade that stimulates GH synthesis and pulsatile release from the pituitary gland. The key difference from ghrelin is that ipamorelin does not activate the parallel receptor pathways that drive hunger, cortisol, and prolactin release.

Synergy with Endogenous GHRH: Ipamorelin's GH release is dramatically amplified when endogenous GHRH signaling is present or when an exogenous GHRH analogue (like CJC-1295) is co-administered. The GHSR-1a and GHRH receptor pathways are genuinely synergistic at the pituitary — both are needed simultaneously to produce a maximal GH pulse. This is the mechanistic basis for the CJC-1295 + ipamorelin stack being so much more effective than either alone.

IGF-1 Downstream Response: Elevated GH from repeated ipamorelin pulses signals the liver to produce Insulin-like Growth Factor 1 (IGF-1), which mediates most of GH's anabolic and body composition effects. Regular ipamorelin use (2–3x daily) raises IGF-1 approximately 15–30% from baseline. When stacked with CJC-1295 DAC, the IGF-1 rise can exceed 50% — important context for monitoring and staying within physiologic reference ranges.

No Desensitization: Unlike some peptides and GH secretagogues, ipamorelin shows no evidence of receptor desensitization at standard doses with ongoing use. This is mechanistically explained by its pulsatile delivery pattern — the receptor is not chronically occupied. Continuous GHSR-1a stimulation (as with some small molecule secretagogues) produces tachyphylaxis; pulsatile agonism as produced by ipamorelin injections does not.